Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia

Biological Psychiatry
A C LahtiC A Tamminga

Abstract

In an ongoing effort to characterize the clinical pharmacologic profile of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine [(-)-3PPP], we administered it to drug-free schizophrenic patients in two consecutive studies. In a preliminary dose-finding study, 9 patients were treated using a 6-week placebo-controlled crossover design. Then, to properly demonstrate the antipsychotic effect, we carried out an early efficacy study; here 10 patients received (-)-3PPP, 300 mg B.I.D., in a 1-week placebo-controlled crossover study. Dose-Finding Study: (-)-3PPP showed apparent antipsychotic effect in repeated dosing, with 300 mg B.I.D. being the most effective dose for antipsychotic action; however, the apparent antipsychotic action was not sustained for longer than 1 week, presumably because of desensitization of the receptor by the agonist. Early Efficacy Study: Positive symptoms as measured by the Psychosis Change Scale decreased in 1 week by 30% with (-)-3PPP compared to placebo, and negative symptoms measured with the Brief Psychiatric Rating Scale Withdrawal subscale decreased by 28% with the drug. In both studies, (-)-3PPP lacked any evidence of motor side effects. These data show that psychotic symptoms dec...Continue Reading

References

Dec 29, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·J R Walters, R H Roth
Jan 1, 1979·Psychopharmacology·C A Tamminga, M H Schaffer
Jan 1, 1977·Journal of Neural Transmission·R C SmithJ M Davis
May 5, 1978·Science·C A TammingaJ M Davis
Jan 1, 1992·Journal of Neural Transmission. General Section·C A TammingaA Carlsson
Nov 1, 1989·Psychiatry Research·B KirkpatrickW T Carpenter
Apr 1, 1986·Archives of General Psychiatry·C A TammingaN L Foster
Sep 1, 1972·The Journal of Pharmacy and Pharmacology·W KehrC Atack
Nov 1, 1972·The British Journal of Psychiatry : the Journal of Mental Science·B M AstrachanG Tucker
Apr 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·I N FerrierT J Crow
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·D V JesteR J Wyatt
Jan 1, 1984·Psychopharmacology Bulletin·C A JohnsK L Davis
Jan 1, 1982·Schizophrenia Bulletin·H E Cannon-SpoorR J Wyatt
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Sep 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·L V MetmanT N Chase
Apr 22, 1996·European Journal of Pharmacology·R A LahtiC A Tamminga

❮ Previous
Next ❯

Citations

May 3, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Johan P RungMaria L Carlsson
Nov 7, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Gerhard GrossKarla U Drescher
Mar 27, 2012·European Child & Adolescent Psychiatry·Eiji Kirino
Sep 22, 2001·Neuroscience and Biobehavioral Reviews·N M RichtandS M Strakowski
Dec 22, 1999·Pharmacology & Therapeutics·G EmilienS Cragg
Mar 17, 2000·Brain Research. Brain Research Reviews·A CarlssonM L Carlsson
Apr 3, 2004·Nature Reviews. Drug Discovery·Bryan L RothWesley K Kroeze
Mar 24, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jonathan D UrbanRichard B Mailman
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·A CarlssonM L Carlsson
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Gerard Marek, Kalpana Merchant
Mar 16, 2004·CNS Drugs·Jeffrey A Lieberman
Jan 1, 2002·Expert Review of Neurotherapeutics·Hugh M Jones, Lyn S Pilowsky
Mar 10, 2004·Current Medical Research and Opinion·Ben Green
Dec 9, 2004·Expert Opinion on Therapeutic Targets·David J Sanger
May 17, 2005·European Journal of Pharmacology·Yoshihiro TadoriTetsuro Kikuchi
Jul 17, 2007·Trends in Pharmacological Sciences·Richard B Mailman
Nov 23, 2010·The International Journal of Neuropsychopharmacology·Sridhar NatesanShitij Kapur
Aug 22, 2009·Annales pharmaceutiques françaises·J Costentin
Jun 29, 2005·Journal of Psychopharmacology·R I Ohlsen, L S Pilowsky
Feb 26, 2016·Nature Communications·Carmen Klein HerenbrinkJ Robert Lane
Nov 29, 2007·The International Journal of Neuroscience·Satoru NakaiTetsuro Kikuchi
Jan 5, 2005·The British Journal of Psychiatry : the Journal of Mental Science·A A Bolonna, R W Kerwin
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Feb 6, 2002·Chembiochem : a European Journal of Chemical Biology·A Carlsson
Oct 12, 2004·CNS Spectrums·Darius K Shayegan, Stephen M Stahl
Sep 8, 2016·The European Journal of Neuroscience·Pierre Sokoloff, Bernard Le Foll
Feb 26, 2019·Journal of Neural Transmission·R Horowski, P-A Löschmann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Neural Transmission. General Section
C A TammingaA Carlsson
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
O BenkertH Wetzel
© 2021 Meta ULC. All rights reserved